MaxCyte

MaxCyte CROIC

The Cash Return on Invested Capital (CROIC) of MaxCyte (MXCT) as of Sep 27, 2026 is -19.10 %. In the previous year, Cash Return on Invested Capital (CROIC) was -13.05 % — a change of 46.39% (lower).

CROIC

-19.10 %

YoY

46.39%

Last updated:

Cash Return on Invested Capital (CROIC) of MaxCyte is 2026 -19.10 % . Cash Return on Invested Capital (CROIC) of MaxCyte was 2025 -13.05 % . It decreases by 46.39% lower compared to the previous year.

The MaxCyte CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-64.58 USD
Jan 1, 2019
-48.40 USD
Jan 1, 2020
-27.01 USD
Jan 1, 2021
-5.40 USD
Jan 1, 2022
-12.32 USD
Jan 1, 2023
-10.12 USD
Jan 1, 2024
-13.05 USD
Jan 1, 2025
-19.10 USD
The MaxCyte CROIC history
YEARCROICYoY
-19.10 %+46.39%
-13.05 %+28.95%
-10.12 %-17.85%
-12.32 %+127.90%
-5.40 %-79.99%
-27.01 %-44.20%
-48.40 %-25.05%
-64.58 %+54.61%
-41.77 %+65.03%
-25.31 %+80.50%
-14.02 %-77.90%
-63.45 %—
Access this data via the Eulerpool API

MaxCyte Stock analysis

What does MaxCyte do? MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MaxCyte stock

Cash Return on Invested Capital (CROIC) of MaxCyte is -19.10 % in 2026.

Cash Return on Invested Capital (CROIC) of MaxCyte changed from -13.05 % to -19.10 %, representing a 46.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) MaxCyte since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s MaxCyte with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

Profitability — MaxCyte

All Key Metrics — MaxCyte